BridgeBio Oncology Therapeutics Inc. (BBOT) Stock

BridgeBio Oncology Therapeutics Inc. (BBOT) is a Healthcare stock trading at $9.08 (as of 2026-08-21), with a market capitalization of $727.98M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

BridgeBio Oncology Therapeutics is a clinical-stage biopharmaceutical company developing next-generation small molecule therapeutics targeting RAS and PI3Kα malignancies, which are prevalent oncogenes in human tumors. Initially formed as a subsidiary of BridgeBio Pharma, it focuses on precision oncology with a pipeline that includes BBO-8520, BBO-10203, and BBO-11818 programs targeting KRAS and PI3K pathways. The company recently went public through a business combination with Helix Acquisition Corp. II, raising approximately $450 million to advance clinical development. The CEO is Dr. Eli Wallace, and the CSO is Dr. Pedro Beltran.

Understand BridgeBio Oncology Therapeutics Inc.: how it makes money

BridgeBio Oncology Therapeutics develops next-generation small-molecule therapeutics for cancers driven by RAS and PI3K alpha malignancies, and it currently has no reported revenue, so its funding and progress depend on advancing its clinical pipeline (and capital raised such as the approximately $450 million public listing).

Because the company is clinical-stage with 0.0B reported revenue (latest quarter ended 2026-03-31), its economic outcome is structurally driven by whether its RAS and PI3K pathway programs (BBO-8520, BBO-10203, BBO-11818) generate convincing clinical results while it raises and deploys capital to fund ongoing development.

Business quality (Weak): Clear development focus with identifiable programs and published clinical-style outcome metrics, but the latest reported quarter shows 0.0B revenue and a very large operating loss, highlighting typical early-stage uncertainty.

Bull case

Pipeline focused on defined oncogenic targets: The company is developing small molecule therapeutics targeting RAS and PI3K alpha malignancies, with named programs including BBO-8520, BBO-10203, and BBO-11818.
Clinical outcome signals in the provided metrics: Provided KPIs include Objective Response Rate of 65% and Six-Month Progression-Free Survival of 66%.
Capital raised to advance development: It recently went public through a business combination with Helix Acquisition Corp. II, raising approximately $450 million to advance clinical development.

Bear case

No current revenue in the latest reported quarter: For the quarter ended 2026-03-31, revenue is shown as 0.0B, consistent with a business model that is not yet monetizing products.
Very large operating loss: The latest reported operating margin is -1170.9, reflecting sustained spending typical of clinical-stage operations.
Clinical success depends on continued trial performance: Even within the provided metrics, the program level detail and durability of outcomes remain uncertain, including Patients Remaining on Study for at Least Six Months of 83%.

Valuation — source: SEC EDGAR (first-party)
Price	$9.08
Market Cap	$727.98M
Price / Book	2.25
Price / Sales	48.91
FCF Yield	-30.8%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$11.34M
Net Margin	-1181.7%
Revenue Growth (YoY)	34.2%
EPS Growth (YoY)	-99.9%
FCF Growth (YoY)	13986.8%

Financial Health — source: SEC EDGAR
Altman Z-Score	10.60 (safe)

Valuation vs Sector & Industry
Sector P/E (Healthcare)	21.7
Industry P/E (Pharmaceutical Products)	17.2

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	Cormorant Asset Management, LP ($160.01M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Eli Wallace
Employees	62
Country	US
IPO Date	2025-08-12

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.